Market research
AKER Akers Biosciences, Inc
NASDAQ USD Healthcare
Latest close
Latest stored close unavailable
Test a moving-average rule with historical data.
Market facts
- Market cap
- 21M
- P/E ratio
- Not available
- Analyst target
- 4
- Dividend yield
- 0.0%
- Beta
- 0.34
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- ISIN
- Not available
- Market cap
- 21M
- P/E ratio
- Not available
- Analyst target
- 4
- Dividend yield
- 0.0%
- Beta
- 0.34
About
About Akers Biosciences, Inc
Akers Biosciences, Inc. focuses on the development of a vaccine candidate against SARS-CoV-2, a coronavirus causing a pandemic. It has a collaboration agreement with Premas Biotech PVT Ltd. The company was incorporated in 1989 and is headquartered in New York, New York.
Research context
Akers Biosciences, Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the AKER discussion.
5 years, 6 months ago
Akers Biosciences, Inc is currently in a long term uptrend where the price is trading 232.5% above its 200 day moving average.
From a valuation standpoint, the stock is 99.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 7.6.
Akers Biosciences, Inc's total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has dropped by 145.4% to $-3M since the same quarter in the previous year.
Finally, its free cash flow fell by 514.3% to $-3M since the same quarter in the previous year.
Based on the above factors, Akers Biosciences, Inc gets an overall score of 2/5.